Raises additional $5.3 mil. through private placement with European venture capitalists. Financing came from Scandinavia firm A.S. Industriforsikring and from Hambrecht & Quist Life Science Ventures, Hambrecht & Quist London, Delphi BioInvestments, Technology Funding Partners III, Ventana Growth Fund, Cabanco Fondkommission and Elf Technology. Telios has raised $22 mil. to date in addition to support received from Ono.
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.